Secondary Logo

Most Popular Articles

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

Durairaj, Chandrasekar; Ruiz-Garcia, Ana; Gauthier, Eric R.; More

Anti-Cancer Drugs. 29(3):271-280, March 2018.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin

Inagaki, Chiaki; Shimoi, Tatsunori; Okuma, Hitomi; More

Anti-Cancer Drugs. 29(1):97-101, January 2018.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models

Capasso, Anna; Pitts, Todd M.; Klauck, Peter J.; More

Anti-Cancer Drugs. 29(9):827-838, October 2018.

Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines

Koukourakis, Michael I.; Kakouratos, Christos; Kalamida, Dimitra; More

Anti-Cancer Drugs. 29(4):323-333, April 2018.

Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group

Pistamaltzian, Nikolaos; Tzannis, Kimon; Pissanidou, Vassiliki; More

Anti-Cancer Drugs. 27(1):48-53, January 2016.

Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

Sanfilippo, Roberta; Dileo, Palma; Blay, Jean-Yves; More

Anti-Cancer Drugs. 26(6):678-681, July 2015.

  • Open Access

Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy

Mitani, Akihisa; Jo, Taisuke; Yasunaga, Hideo; More

Anti-Cancer Drugs. 29(6):560-564, July 2018.

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Bernier, Cynthia; Soliman, Ahmed; Gravel, Michel; More

Anti-Cancer Drugs. 29(8):774-785, September 2018.

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies

Rixe, Olivier; Puzanov, Igor; LoRusso, Patricia M.; More

Anti-Cancer Drugs. 26(7):785-792, August 2015.

Anticancer properties of thiophene derivatives in breast cancer MCF-7 cells

Dos Santos, Flaviana Alves; Pereira, Michelly Cristiny; de Oliveira, Tiago Bento; More

Anti-Cancer Drugs. 29(2):157-166, February 2018.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

Leonard, Shannon C.; Lee, Helen; Gaddy, Daniel F.; More

Anti-Cancer Drugs. 28(10):1086-1096, November 2017.

Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes

Caballero Romero, Álvaro; Delgado Ureña, María Teresa; Salmerón García, Antonio; More

Anti-Cancer Drugs. 29(9):821-826, October 2018.

Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells

Momeny, Majid; Eyvani, Haniyeh; Barghi, Farinaz; More

Anti-Cancer Drugs. 29(10):1011-1020, November 2018.

Phase 1 study of escalating-dose OncoGel® (ReGel®/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions

Vukelja, Svetislava J.; Anthony, Stephen P.; Arseneau, James C.; More

Anti-Cancer Drugs. 18(3):283-289, March 2007.

Show: